Navigation Links
MIGENIX Reports First Quarter Fiscal 2009 Financial Results
Date:9/15/2008

t believes that the expectations represented by such forward-looking statements are reasonable, there is significant risk that the forward-looking statements may not be achieved, and the underlying assumptions thereto will not prove to be accurate. Forward-looking statements in this news release include, but are not limited to, statements concerning our expectations for: raising up to $2.5 million through a rights offering; Cadence Pharmaceuticals having top-line results of the OmigardTM Phase III CLIRS trial in the first quarter of calendar 2009 and if the results of this trial are positive, Cadence submitting a new drug application (NDA) for OmigardTM in the second quarter of calendar 2009; completing rest of world partnership(s) for OmigardTM after positive OmigardTM CLIRS study results; Cutanea Life Sciences' plans to submit a NDA in 2011 including initiating chronic toxicology studies in the first quarter of calendar 2009 and advancing omiganan for the treatment of rosacea into Phase III clinical development in the second half of calendar 2009; MX-2401 being our next clinical program and our plans to continue key development activities to support the MX-2401 program; receiving up to US$27 million in milestone payments pursuant to our agreements with Cadence; continuing to pursue a partner for the further development of celgosivir; and the Company's financial resources being sufficient to fund operations to approximately the end of calendar 2008.

With respect to the forward-looking statements contained in this news release, we have made numerous assumptions regarding, among other things: our ability to complete a rights offering; the adequacy of the OmigardTM Phase III trial design to generate data that are deemed sufficient by regulatory authorities to support potential regulatory filings, including an NDA, for OmigardTM; Cutanea's ability to manage, fund and advance omiganan for dermatological applications into Phase III and submit a NDA; our ability to
'/>"/>

SOURCE MIGENIX Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Migenix averts proxy contest; reaches agreement with DJohnson holdings
2. Notice of MIGENIX General Meeting of Shareholders
3. MIGENIX Fourth Quarter and Fiscal Year 2008 Financial Results Conference Call & Webcast Notification
4. MIGENIX Corporate Update and Requisition of Special Meeting
5. Migenix Takes Operational Actions To Extend Cash Past Upcoming Key Milestones
6. MIGENIX Appoints Pieter Dorsman to Board of Directors
7. MIGENIX Reports Third Quarter Fiscal Year 2008 Financial Results
8. MIGENIX Third Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
9. MIGENIX releases CEO message #22
10. MIGENIX to Add 600mg Daily Celgosivir Dose to Phase II Viral Kinetics Study
11. MIGENIX Reports Second Quarter Fiscal Year 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... , Aug. 31, 2015  RXi Pharmaceuticals Corporation ... on discovering and developing innovative therapies primarily in ... that the 30-day review period following the filing ... ocular indications with the U.S. Food and Drug ... now active. Logo -  ...
(Date:8/31/2015)... SHANGHAI , Aug. 31, 2015  MicuRx ... antibiotics, today announced positive top-line results from the ... drug candidate MRX-I. MRX-I is an oral oxazolidinone ... MRSA and VRE, while offering physicians and patients ... currently available oxazolidinone agents. "These ...
(Date:8/31/2015)... LabStyle Innovations Corp. (OTCQB: DRIO), developer ... it recently closed a round of funding totaling ... support the global rollout and initial U.S. commercial ... management solution that includes novel software applications combined ... device, and for working capital purposes. The Dario ...
(Date:8/31/2015)... Grove, IL (PRWEB) , ... August 31, 2015 ... ... impurities (PGIs), as a high priority in the drug development approval process. Thus, ... , This year, Regis Technologies, Inc., a Chicago-based CMO, has been hosting ...
Breaking Biology Technology:RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 2RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 3RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 4MicuRX Reports Positive Top-Line Results In Phase 2 Clinical Trial For Novel Antibiotic MRX-I In Complicated Skin And Soft Tissue Infections 2LabStyle Innovations Closes $2.5 Million Funding to Support Global Rollout of Dario Diabetes Management Solution 2LabStyle Innovations Closes $2.5 Million Funding to Support Global Rollout of Dario Diabetes Management Solution 3LabStyle Innovations Closes $2.5 Million Funding to Support Global Rollout of Dario Diabetes Management Solution 4Regis Shares Expert Advice on Impurities in Drug Development 2Regis Shares Expert Advice on Impurities in Drug Development 3
... Pearl Therapeutics announced,today that it has secured $8 ... Silicon Valley Bank, a member company of SVB Financial,Group ... will be drawn in two,tranches. , ... Oxford and SVB. They are,experienced and committed lenders ...
... 24 An investor group in Trinity,Biotech plc (Nasdaq: ... manufacturer of,diagnostic products, has petitioned the Office of the ... law provisions designed,to permit communication between shareholders and prospective ... filed asserts that Irish-based independent directors,Peter Coyne of Allied ...
... VITAS Innovative Hospice Care(R) announced,today that Christopher ... chief,information officer. In his new position, Rieder will ... to support the company,s,strategic direction. , ... of IT experience with global organizations,translating business objectives ...
Cached Biology Technology:Pearl Therapeutics Secures $8 Million in Debt Financing 2Pearl Therapeutics Secures $8 Million in Debt Financing 3VITAS Innovative Hospice Care(R) Names Christopher Rieder Senior Vice President and Chief Information Officer 2
(Date:8/5/2015)... Aug. 5, 2015 The biosensors market is ... applications, penetration into newer sectors, and development of devices ... biosensors space has seen the entry of multiple participants ... far. (Photo - http://photos.prnewswire.com/prnh/20150805/255570 ) ... Analysis of the Global Biosensors Market ( http://www.frost.com/nee9 ...
(Date:7/31/2015)... , 31 de julio de 2015 ... (ICG-10,  www.icg-10.org ) del 22 al 25 de octubre ... La conferencia celebra su décimo aniversario este ... convertido en una de las reuniones anuales más influyentes ... es una de las conferencias científicas más dinámicas, entusiastas ...
(Date:7/31/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... growing mobile commerce market and creator of the Wocket® ... 62/198989 for ELECTRONIC CRYPTO-CURRENCY MANAGEMENT METHOD AND ... advance crypto-currencies such as Bitcoin into the consumer market ... to manage all payments.  The technology ...
Breaking Biology News(10 mins):Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3NXT-ID Patents Electronic Crypto-Currency Management Technology 2NXT-ID Patents Electronic Crypto-Currency Management Technology 3NXT-ID Patents Electronic Crypto-Currency Management Technology 4
... air pollutant that harms humans and plants. Both climate and ... Researchers at the University of Gothenburg, Sweden, have now shown ... risk of ozone damage to plants in northern and central ... risk of ozone damage to vegetation is mainly due to ...
... German . When a cell divides, the ... to the daughter cells. Researchers at the Friedrich Miescher Laboratory ... a model organism. In cooperation with researchers at the University ... Aurora enzymes, which were already recognized as important cellular tools ...
... of engineers and scientists at the University of British Columbia ... eye for controlled and on-demand release of drugs to treat ... leading cause of vision loss among patients with diabetes. The ... in the retina, which in its advanced stages can result ...
Cached Biology News:Climate change increases the risk of ozone damage to plants 2New tasks attributed to Aurora proteins in cell division 2New tasks attributed to Aurora proteins in cell division 3UBC researchers invent new drug delivery device to treat diabetes-related vision loss 2
... SAPK/JNK (Thr183/Tyr185) Antibody Kit Kit ... Catalog #9251, 200 ul SAPK/JNK (56G8) ... SAPK/JNK Cell Extracts, Catalog #9253, (4 ... Catalog #7074, 100 ul Anti-biotin IgG, ...
100 g monoclonal antibody which can immunocapture ~10 g of Complex IV from heart mitochondria. Also included are 2 mg of bovine heart mitochondria for control immunocapture....
Anti-gp120/160(SIV/mac239) Immunogen: gp120(SIV/mac239) protein (Genebank accession #M33262)...
Rabbit polyclonal to GPR56 ( Abpromise for all tested applications). entrezGeneID: 9289 SwissProtID: Q9Y653...
Biology Products: